Hemab Therapeutics has initiated SOLARA, a pivotal Phase 3 clinical trial testing sutacimig, a once-weekly subcutaneous antibody, as a preventive treatment for Glanzmann thrombasthenia (GT), a rare bleeding disorder with no approved prophylactic therapies. The trial will enroll about 75 participants and compare bleeding rates during a 24-week run-in period with 48 weeks of sutacimig treatment. Early Phase 2 data showed sutacimig significantly reduced bleeding events and was generally well tolerated. If successful, sutacimig could become the first approved preventive therapy for GT, improving quality of life for patients who currently manage unpredictable bleeding episodes without prophylaxis.
Hemab Therapeutics' new Phase 3 trial of sutacimig in Glanzmann thrombasthenia provides context for health sector activity on Pluang. As of Nov 09, 2026 18:41 WIB, 108 of 150 priced health-sector US stocks rose while 26 fell. Notable movers include ROIV at USD 40.39 with a 3.88% gain and NUWE at USD 4.74 with a 3.49% increase.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
